Terminated PHASE1 INTERVENTIONAL 1-arm NCT00424489

Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis

Sponsor: Northwestern University

Interventions ATG (rabbit) Cyclophosphamide G-CSF Hematopoietic Stem Cell Transplantation Mesna Methylprednisolone

Updated 8 times since 2017 Last updated: Aug 3, 2018 Started: Feb 28, 2002 Primary completion: Jun 30, 2016 Completion: Jun 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

No participants enrolled for more than two years. No plan to continue study.

Other terminated trials from Northwestern University

See all terminations from Northwestern University

Other Myasthenia Gravis trials with similar outcome

Browse all Myasthenia Gravis trials

A PHASE1 clinical study on Myasthenia Gravis, this trial is terminated or withdrawn. The trial is conducted by Northwestern University and has accumulated 8 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE1
Sep 2018 — Jan 2021 [monthly]

Terminated PHASE1

▶ Show 3 earlier versions

Jun 2018 — Sep 2018 [monthly]

Terminated PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Feb 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Northwestern University

Data source: Northwestern University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States